168 related articles for article (PubMed ID: 20483636)
21. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
22. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta.
Rameshwar P; Denny TN; Stein D; Gascón P
J Immunol; 1994 Sep; 153(6):2819-30. PubMed ID: 7521370
[TBL] [Abstract][Full Text] [Related]
23. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
Dai SM; Matsuno H; Nakamura H; Nishioka K; Yudoh K
Arthritis Rheum; 2004 Feb; 50(2):432-43. PubMed ID: 14872485
[TBL] [Abstract][Full Text] [Related]
25. Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure.
Conraads VM; Bosmans JM; Schuerwegh AJ; Goovaerts I; De Clerck LS; Stevens WJ; Bridts CH; Vrints CJ
J Heart Lung Transplant; 2005 Jul; 24(7):854-9. PubMed ID: 15982613
[TBL] [Abstract][Full Text] [Related]
26. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
[TBL] [Abstract][Full Text] [Related]
27. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
28. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
29. Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders.
Sozer S; Wang X; Zhang W; Fiel MI; Ishii T; Wang J; Wisch N; Xu M; Hoffman R
Blood Cells Mol Dis; 2008; 41(3):284-91. PubMed ID: 18715806
[TBL] [Abstract][Full Text] [Related]
30. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
31. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
32. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
[No Abstract] [Full Text] [Related]
33. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
Medeiros BC; Zhang T; Lipton JH; Kamel-Reid S
Am J Hematol; 2007 Apr; 82(4):293-4. PubMed ID: 17013813
[TBL] [Abstract][Full Text] [Related]
34. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
Chen YX; Li Y; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia.
Martínez-Avilés L; Álvarez-Larrán A; Besses C; Navarro G; Torres E; Longarón R; Angona A; Pedro C; Florensa L; Serrano S; Bellosillo B
Ann Hematol; 2012 Oct; 91(10):1555-62. PubMed ID: 22706669
[TBL] [Abstract][Full Text] [Related]
36. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status.
Heller PG; Lev PR; Salim JP; Kornblihtt LI; Goette NP; Chazarreta CD; Glembotsky AC; Vassallu PS; Marta RF; Molinas FC
Eur J Haematol; 2006 Sep; 77(3):210-6. PubMed ID: 16923108
[TBL] [Abstract][Full Text] [Related]
37. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
[TBL] [Abstract][Full Text] [Related]
38. [JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation].
Sun CC; Li Y; Tian WJ; Chen YJ; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1022-6. PubMed ID: 25130821
[TBL] [Abstract][Full Text] [Related]
39. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
[TBL] [Abstract][Full Text] [Related]
40. Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.
Strobbe L; Lestrade P; Hermans MH; Fijnheer R
Ann Hematol; 2007 Nov; 86(11):801-3. PubMed ID: 17703302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]